The Technical Analyst
Mainz Biomed B.V. [MYNZ]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Mainz Biomed B.V. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.08% $0.871
America/New_York / 22 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 14.58 mill |
| EPS: | -1.620 |
| P/E: | -0.540 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 16.75 mill |
| Avg Daily Volume: | 0.0835 mill |
| RATING 2024-04-22 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | ||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.540 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.540 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.787 - 0.955 ( +/- 9.65%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.871
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.871
Forecast 2: 16:00 - $0.871
Forecast 3: 16:00 - $0.871
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.871 (-1.08% ) |
| Volume | 0.0664 mill |
| Avg. Vol. | 0.0835 mill |
| % of Avg. Vol | 79.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MYNZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MYNZ
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Latest Press Releases
2024-04-09 08:01:00 - Press Release
Mainz Biomed Reports Full Year 2023 Financial Results
Berkeley, calif. and mainz, germany, april 09, 2024 (globe newswire) -- mainz biomed n.v.
2024-03-19 08:01:00 - Press Release
Mainz Biomed Organizes Hallo Doc! Event To Highlight Innovations In Colorectal Cancer Treatment
Berkeley, calif. and mainz, germany, march 19, 2024 (globe newswire) -- mainz biomed n.v.
2024-03-18 08:01:00 - Press Release
Mainz Biomed: Webinar On Early Detection Of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
Berkeley, calif. and mainz, germany, march 18, 2024 (globe newswire) -- mainz biomed n.v.
2024-03-12 08:01:00 - Press Release
Mainz Biomed Presents Coloalert® At Udh Congress 2024: Leading The Way In Evidence-based Cancer Screening Innovations
Berkeley, calif. and mainz, germany, march 12, 2024 (globe newswire) -- mainz biomed n.v.
2024-03-05 08:01:00 - Press Release
Mainz Biomed Partners With Trusted Health Advisors To Support U.s. Go-to-market Strategy For Next Generation Early Colorectal Cancer Diagnostic
Dr. jay wohlgemuth, former chief medical & scientific officer of quest diagnostics and dr. ray tabibiazar, a seasoned industry executive, to lead collaboration mainz biomed's pivotal fda pma clinical trial (reconaasense) evaluating gold standard self-administered colorectal cancer screening test on track to commence patient enrollment in 2024 berkeley, calif. and mainz, germany, march 05, 2024 (globe newswire) -- mainz biomed n.v.
Latest News
2024-03-08 13:01:06 - Zacks Investment Research
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-12-19 15:39:28 - Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study - Exact Sciences (NASDAQ:EXAS), Mainz Biomed (NASDAQ:MYNZ)
Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.
2023-11-29 08:01:00 - GlobeNewsWire
Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
2023-11-20 08:01:00 - GlobeNewsWire
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-01 08:40:09 - InvestorPlace
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagnostic company shared results from a colorectal cancer screening test campaign. The company held this screening test campaign with the help of partner Zöller-Kipper GmbH.
2023-09-27 08:01:00 - GlobeNewsWire
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group's 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology BERKELEY, Calif. and MAINZ, Germany, Sept.
2023-09-20 03:01:00 - GlobeNewsWire
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference which takes place September 26-28, 2023 in New York City.
2023-08-29 03:01:00 - GlobeNewsWire
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4
2023-03-21 03:01:00 - GlobeNewsWire
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Bill Caragol, the Company's CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023. The presentation will begin at 12:15 ET on March 22, 2023 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_apzthw9PRlOrUq5PSD5Dcw. Mainz Biomed will also host virtual one-on-ones with investors on Wednesday and Thursday, March 22-23, 2023. To register for the presentation or one-on-ones, visit www...
2022-10-30 02:16:18 - Seeking Alpha
Mainz Biomed: A Long-Term Bet Relying On Expanded Testing
Mainz Biomed is a German developer of genetic tests for various diseases, primarily cancer. At the moment, the company has one main product, ColoAlert, a colorectal cancer test that is so far only approved in some non-US countries.